(24/7 MARKET NEWS) – Equillium Inc. (NASDAQ: EQ) is in the green on positive interim results, from the Type B portion of the EQUALISE study evaluating itolizumab, in patients with lupus nephritis (LN).
Equillium is at $2.3671, a gain of $0.4371 (+22.65%), on 5,153,665 shares traded. It opened this morning at $2.23 and traded as high as $2.52. Its 52-week range is $1.66 to $7.12 and this morning’s volume is, by far, the most in that time frame.
To view the full press release, please go to: https://www.businesswire.com/news/home/20220927005571/en/.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
